// App-Quantinova.ai

4634 : Novel dual HDAC & PI3K inhibitor, CUDC-907, for MYC-driven malignancies

Researchers

Presenter

  • Kaiming Sun

Principal Investigators

  • Ruzanna Atoyan

  • Mylissa A. Borek

  • Steven Dellarocca

  • Maria E. Samson

  • Anna W. Ma

  • Guangxin Xu

  • Troy Patterson

  • David P. Tuck

  • Jaye L. Viner

  • Ali Fattaey

  • Jing Wang

Medical Centers

  • Curis, Lexington, MA

Locations

  • United States

Companies

  • Curis, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

Drug/Treatment

  • CUDC-907

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved